Cynthia Chmielewski | CureTalks
Cynthia attended Rutgers University graduating with degrees in Psychology and Education. Upon graduation she secured her first teaching position and immediately fell in love with her chosen profession. Cynthia continued teaching for 28 years. Now retired, Cynthia, a myeloma survivor, is using her passion for education to teach a new group of "students" - myeloma patients and their caregivers. She is on the advisory boards of the Patient Empowerment Network, the Myeloma Crowd and the Philadelphia Multiple Myeloma Networking Group. Using social media to educate is her passion. Cynthia educates and advocates by tweeting at @MyelomaTeacher and sharing myeloma resources, educational opportunities and clinical trial information on her MyelomaTeacher Facebook page. Ms. Chmielewski is the co-founder of the #MMSM TweetChat and is also a regular panelist on CureTalks Podcast. Cynthia was an invited panelist and presented posters on using social media in hematology at the annual meetings of the American Society of Hematology (ASH), the American Association for Cancer Research (AACR) and the European Bone Marrow Transplant (EBMT). More recently Cynthia joined the Patient Engagement team at Patient Power. Additionally, she consults on educational projects sponsored by the Myeloma Crowd. She enjoys serving as a voting member on the IRB at the University of Pennsylvania, a peer reviewer for the NCI’s DEA grants program and a patient advocate on the Myeloma Steering Committee of the National Cancer Institute (NCI) and ACCRU. Cynthia has also participated in the Department of Defense’s CMCRP grant reviews.
Related Talks
Transplants and Risk Adapted Maintenance in Myeloma Treatment
The treatment paradigm for myeloma patients has changed in the last decade with important advancements such as proteasome inhibitors, IMiDS, antibodies and risk-adapted…
Inherited Gene Mutations in Myeloma and Role of Precision Medicine
Multiple Myeloma is the second most common cancer of the blood and is largely incurable. A recent study has found that a specific…
Multiple Myeloma: An Insight into Early Intervention and Personalized Therapies
Myeloma patients are definitely living longer. A decade ago the median survival was 3 to 4 years, while now it is in the…
Myeloma 2017 – Year in Review with MMRF
The MMRF is pioneering precision medicine initiatives in multiple myeloma. This would help match patients to the most effective therapies based on their…
Targeting Stem Cells in Multiple Myeloma for Improved Outcomes
Multiple myeloma remains incurable despite improved remissions with novel agents. Relapse eventually occurs in the form of drug-resistant disease that carries a dismal…